Astrazeneca (AZN) Non-Current Deferred Tax Liability (2009 - 2026)
Astrazeneca (AZN) posted quarterly Non-Current Deferred Tax Liability of $3.5 billion for Q2 2026, down 4.2% year-over-year from $3.6 billion in Q2 2025, and up 199.77% quarter-over-quarter from -$3.5 billion in Q1 2026.
Astrazeneca (AZN) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends
Astrazeneca's Non-Current Deferred Tax Liability history runs 18 years deep, the most recent figure standing at $3.5 billion for Q2 2026.
- In Q2 2026, Non-Current Deferred Tax Liability fell 4.2% year-over-year to $3.5 billion; the TTM figure through Jun 2026 stood at $3.5 billion (down 4.2% YoY), while the FY2025 annual figure was $3.5 billion, down 32.16% from the prior year.
- Non-Current Deferred Tax Liability for Q2 2026 stood at $3.5 billion, up from -$3.5 billion in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $5.2 billion in Q4 2024, with the low at -$5.6 billion in Q1 2022.
- The 5-year median for Non-Current Deferred Tax Liability is -$2.8 billion (2023), against an average of -$1.2 billion.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deferred Tax Liability sank 152.24% in 2022, then surged 208.46% in 2025.
- Astrazeneca's Non-Current Deferred Tax Liability stood at $2.9 billion in 2022, then declined by 3.4% to $2.8 billion in 2023, then jumped by 81.4% to $5.2 billion in 2024, then sank by 32.16% to $3.5 billion in 2025, then fell by 1.06% to $3.5 billion in 2026.
- Business Quant data shows AZN's Non-Current Deferred Tax Liability at $3.5 billion in Q2 2026, -$3.5 billion in Q1 2026, and $3.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.46 Bn |
| Jun 30, 2026 | 3.46 Bn |
| Mar 31, 2026 | -3.47 Bn |
| Mar 31, 2026 | -3.47 Bn |
| Dec 31, 2025 | 3.50 Bn |
| Dec 31, 2025 | 3.50 Bn |
| Sep 30, 2025 | -3.60 Bn |
| Sep 30, 2025 | -3.60 Bn |
| Jun 30, 2025 | 3.62 Bn |
| Jun 30, 2025 | 3.62 Bn |
| Mar 31, 2025 | -3.55 Bn |
| Mar 31, 2025 | -3.55 Bn |
| Dec 31, 2024 | 5.16 Bn |
| Dec 31, 2024 | 5.16 Bn |
| Sep 30, 2024 | -3.57 Bn |
| Sep 30, 2024 | -3.57 Bn |
| Jun 30, 2024 | -3.33 Bn |
| Jun 30, 2024 | -3.33 Bn |
| Mar 31, 2024 | -2.62 Bn |
| Mar 31, 2024 | -2.62 Bn |